

Data S1. Cell proliferation assay.

## **Supplementary methods**

### **Cell proliferation assay**

The proliferation of SACC cells was determined using a Cell Counting Kit-8 (CCK-8, Dojindo, Molecular Technologies, Inc., Kumamoto, Japan) according to the manufacturer's instructions. SACC cells transfected with miR-103a-3p mimics, miR-103a-3p inhibitor, TPD52 siRNA, TPD52 overexpression plasmid and their negative controls were plated at a density of  $5 \times 10^3$  cells per well in 96-well plates and incubated overnight in RPMI 1640 medium supplemented with 10% FBS. At 0, 24, 48, and 72 hours after cells adhered to the surface of culture plates, 10  $\mu$ l of CCK-8 reagent was added to the test well and incubated for 2-3 h. The absorbance was measured at 450 nm using an ELx808 Absorbance Microplate Reader (BioTek Instruments, Inc., Winooski, VT, USA).

Figure S1. miR-103a-3p has no effect on SACC cell proliferation. (A) CCK-8 proliferation assay results for SACC-83 cells transfected with the miR-103a-3p mimics and mimics negative control. (B) CCK-8 proliferation assay results for SACC-LM cells transfected with the miR-103a-3p inhibitor and inhibitor negative control.




Figure S2. TPD52 has no effect on SACC cell proliferation. (A) CCK-8 proliferation assay results for SACC-LM cells transfected with the TPD52- overexpressing plasmid and empty vector. (B) CCK-8 proliferation assay results for SACC-83 cells transfected with the two TPD52 siRNAs and the negative control construct.




Table SI. Correlations between clinicopathological variables and TPD52 expression in patients with salivary adenoid cystic carcinoma.

Variables	TPD52 expression			$\chi^2$	P-value
	Total (n)	Low (n)	High (n)		
Age, years				0.083	0.773
<42	19	10	9		
$\geq$ 42	33	16	17		
Sex				2.769	0.096
Male	26	16	10		
Female	26	10	16		
Tumour size				0.239	0.625
<4 cm	35	19	16		
$\geq$ 4 cm	17	8	9		
Clinical stage <sup>a</sup>				0.000	1.000
I/II	16	8	8		
III/IV	36	18	18		
Site				0.000	1.000
Major salivary gland	12	6	6		
Minor salivary gland	40	20	20		
Lymph node metastasis				0.391	0.532
Absent	38	18	20		
Present	14	8	6		
Perineural invasion				4.690	0.030
Absent	24	10	14		
Present	28	20	8		
Lung metastasis				3.900	0.048
Absent	40	17	23		
Present	12	9	3		
Local regional recurrence				1.981	0.159
Absent	42	19	23		
Present	10	7	3		
Pathological type				3.059	0.080
Cribriform/tubular	34	14	20		
Solid	18	12	6		

<sup>a</sup>Clinical stage was determined by the 7th edition of classification system of the Union for International Cancer Control. PD52, Tumour protein D52.